A Ubiquitination Cascade Regulating the Integrated Stress Response and Survival in Carcinomas

Author:

Cervia Lisa D.12ORCID,Shibue Tsukasa1ORCID,Borah Ashir A.1ORCID,Gaeta Benjamin1ORCID,He Linh1ORCID,Leung Lisa1ORCID,Li Naomi12ORCID,Moyer Sydney M.12ORCID,Shim Brian H.12ORCID,Dumont Nancy1ORCID,Gonzalez Alfredo1ORCID,Bick Nolan R.1ORCID,Kazachkova Mariya1ORCID,Dempster Joshua M.1ORCID,Krill-Burger John Michael1ORCID,Piccioni Federica1ORCID,Udeshi Namrata D.1ORCID,Olive Meagan E.1ORCID,Carr Steven A.1ORCID,Root David E.1ORCID,McFarland James M.1ORCID,Vazquez Francisca1ORCID,Hahn William C.12ORCID

Affiliation:

1. 1Broad Institute of MIT and Harvard, Cambridge, Massachusetts.

2. 2Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Abstract

AbstractSystematic identification of signaling pathways required for the fitness of cancer cells will facilitate the development of new cancer therapies. We used gene essentiality measurements in 1,086 cancer cell lines to identify selective coessentiality modules and found that a ubiquitin ligase complex composed of UBA6, BIRC6, KCMF1, and UBR4 is required for the survival of a subset of epithelial tumors that exhibit a high degree of aneuploidy. Suppressing BIRC6 in cell lines that are dependent on this complex led to a substantial reduction in cell fitness in vitro and potent tumor regression in vivo. Mechanistically, BIRC6 suppression resulted in selective activation of the integrated stress response (ISR) by stabilization of the heme-regulated inhibitor, a direct ubiquitination target of the UBA6/BIRC6/KCMF1/UBR4 complex. These observations uncover a novel ubiquitination cascade that regulates ISR and highlight the potential of ISR activation as a new therapeutic strategy.Significance:We describe the identification of a heretofore unrecognized ubiquitin ligase complex that prevents the aberrant activation of the ISR in a subset of cancer cells. This provides a novel insight on the regulation of ISR and exposes a therapeutic opportunity to selectively eliminate these cancer cells.See related commentary Leli and Koumenis, p. 535.This article is highlighted in the In This Issue feature, p. 517

Funder

National Cancer Institute

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3